7704-67-8 Erythromycin Thiocyanate Manufacturer CAS NO.7704-67-8

 Erythromycin Thiocyanate, tonsillitis caused by clinical mainly used in streptococcus, scarlet fever, diphtheria and carrier, gonorrhea, listeria disease, streptococcus pneumoniae lower respiratory tract infection (above applies to patients is not resistant to penicillin for legionella pneumonia and mycoplasma pneumonia, this product can be used as the preferred drug application. Can be applied to the upper respiratory tract infection caused by influenza bacillus and staphylococcus aureus skin and soft tissue infection, syphilis, and intestinal amebiasis.

Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the ''''P'''' or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the ''''A'''' or acceptor site to the ''''P'''' or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.

This product is a veterinary drug for gram positive bacteria and mycoplasma infection;More and more as the initial raw materials used in the synthesis of erythromycin, luo erythromycin, azithromycin, clarithromycin and other large ring lactone class antibiotic.

Antibacterial spectrum and penicillin similar, and mycoplasma, chlamydia, rickettsia, etc., and Legionella have an antibacterial effect.
Suitable for mycoplasma pneumonia, neonatal conjunctivitis caused by Chlamydia trachomatis, infant pneumonia, genitourinary tract infections (including non-gonococcal urethritis)